60 Degrees Pharmaceuticals opens site for chronic babesiosis study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. FLG
4. GMAB
5. ACCV
6. SPCX
7. XNCR
8. AZN
9. APO
10. META

Go back to 60 Degrees Pharmaceuticals opens site for chronic babesiosis study

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

November 21, 2025 8:01 AM EST

90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing FDA-approved treatment for babesiosis

WASHINGTON, Nov. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals,... More